Oncolytics Biotech (ONCY) soars 20.3% after saying its Reolysin treatment, in combination with...

|By:, SA News Editor

Oncolytics Biotech (ONCY) soars 20.3% after saying its Reolysin treatment, in combination with carboplatin and paclitaxel, performed well in a Phase III trial of patients with head and neck cancer. Of 105 patients, 86% exhibited tumour stabilization or shrinkage vs 67% in the control group. The combo including Reolysin was also better at shrinking tumors than the two other treatments on their own. (PR)